Abnormal empathy-like pro-social behaviour in the valproic acid model of autism spectrum disorder
May 17, 2019·,,,
,,,,,·
0 min read
Mellanie Fontes-Dutra
Gustavo Della-Flora Nunes
Júlio Santos-Terra
Walquíria Souza-Nunes
Guilherme Bauer-Negrini
Mauro Mozael Hirsch
Lily Green
Rudimar Riesgo
Carmem Gottfried
Victorio Bambini-Junior
Abstract
Impairments in social behaviour are a defining feature of autism spectrum disorder (ASD). Individuals with ASD also usually present some difficulty to recognize or understand another person’s feelings. Therefore, it is possible that altered empathy processing could hinder typical social interaction in ASD. Recently, robust paradigms confirmed that rodents show primordial forms of empathy-like behaviour. Therefore, in this work, we used one of these new protocols to test pro-social behaviour in the rat model of autism induced by Valproic Acid (VPA). We also evaluated possible beneficial effects of Resveratrol, since it can prevent social deficits in the VPA model. Rats were tested on their ability to open a restrainer to release a trapped conspecific. Exposure to VPA precludes the timely manifestation of this empathy-like behaviour, but does not affect its continuation after its first expression. We also found a significant correlation between average speed during the first day of test and becoming an Opener. Similarly, rats able to open the restrainer on the first day had an increased likelihood of repeating this behaviour in the later days of the testing programme. We did not find any protective effects of Resveratrol. Further investigation of empathy-like behaviour in the VPA model and in other models of autism could help to clarify the behavioural and neural processes underpinning the basic aspects of empathy alterations in autistic individuals.
Type
Publication
Behavioural Brain Research
Status
Peer-reviewed

Authors
Biomedical Data Scientist
Computational neuroscientist working at the intersection of machine learning, biomedical
imaging, and human genetics in neurodegenerative disease. My work applies deep learning to
high-dimensional medical images, harmonizes imaging measurements across sites and acquisition
protocols, and integrates imaging with genomic, proteomic, and longitudinal clinical data to
characterise Alzheimer’s disease and related dementias, with particular focus on fluid and
imaging biomarkers of neurodegeneration.